Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Amgen (AMGN) KYPROLIS Efficacy Strong But Safety Concerns Could Impact Adoption, BMO Capital Says
May 14, 2015 8:17 AM EDTBMO Capital analyst Jim Birchenough weighed in on Amgen (NASDAQ: AMGN) as the company will present several sets of KYPROLIS myeloma data at ASCO including from ENDEAVOR. As previously announced, KYPROLIS dex (Kd) increased PFS over VELCADE dex (Vd) in RRMM patients 18.7 vs. 9.7 mo. The abstract notes that median duration of treatment was... More
Amgen (AMGN) Says ASCO Data to Highlight Oncology Pipeline And Portfolio
May 13, 2015 5:02 PM EDTAmgen (NASDAQ: AMGN) today announced that data at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) will showcase the Company's continued efforts across both pipeline and marketed products, including key results in the treatment of solid tumors and hematologic malignancies.
"The data at ASCO reflect our significant progress in developing treatments across our oncology pipeline and portfolio," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Our focus is to address unmet needs for patients by translating innovation in... More
